Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A new beta-adrenoceptor blocking agent derived from dehydrozingerone

B N Wu1, C R Yang, J M Yang

  • 1Department of Pharmacology, Kaohsiung Medical College, Taiwan, Republic of China.

General Pharmacology
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Clinical efficacy of free anterolateral thigh tissue flap transplantation with a single-vein dual-drainage system at recipient site in repairing scalp high-voltage electrical burn wounds].

Zhonghua shao shang yu chuang mian xiu fu za zhi·2025
Same author

[Hoyeraal-Hreidarsson syndrome with combined immunodeficiency and enterocolitis caused by a DCK1 gene variant].

Zhonghua er ke za zhi = Chinese journal of pediatrics·2022
Same author

Downregulation of Adhesion Molecule CHL1 in B Cells but Not T Cells of Patients with Major Depression and in the Brain of Mice with Chronic Stress.

Neurotoxicity research·2020
Same author

[A novel compound heterozygous variation in ABCA3 gene in a child with interstitial lung disease].

Zhonghua er ke za zhi = Chinese journal of pediatrics·2020
Same author

Antidepressant Drugs Correct the Imbalance Between proBDNF/p75NTR/Sortilin and Mature BDNF/TrkB in the Brain of Mice with Chronic Stress.

Neurotoxicity research·2019
Same author

[Clinicopathological features of follicular lymphoma in children].

Zhonghua bing li xue za zhi = Chinese journal of pathology·2019

Dehydrozingeronolol (DZPN) acts as a beta-adrenoceptor antagonist, showing dose-dependent bradycardia and pressor effects in rats. It selectively inhibits beta-adrenergic responses, indicating potential cardiovascular applications.

Area of Science:

  • Pharmacology
  • Cardiovascular Research
  • Adrenergic Receptor Antagonism

Background:

  • Beta-adrenoceptors play a crucial role in regulating heart rate and vascular tone.
  • Selective antagonists are valuable tools for understanding and modulating adrenergic signaling.
  • Dehydrozingeronolol (DZPN) is a compound with potential beta-adrenergic blocking properties.

Purpose of the Study:

  • To investigate the cardiovascular effects of Dehydrozingeronolol (DZPN) in vivo and in vitro.
  • To characterize the beta-adrenoceptor antagonist activity of DZPN.
  • To compare the potency of DZPN with known beta-blockers.

Main Methods:

  • In vivo studies using urethane-anesthetized normotensive rats to assess hemodynamic effects (heart rate, blood pressure).

Related Experiment Videos

  • In vitro studies using isolated guinea-pig atria and rat uterus horns to evaluate chronotropic and relaxant responses.
  • Radioligand binding assays using [3H]dihydroalprenolol to determine receptor affinity.

    • Main Results:

    • DZPN induced a dose-dependent bradycardia and sustained pressor response in rats.
    • DZPN antagonized (-)isoproterenol-induced tachycardia and atrial contractions but not phenylephrine-induced pressor responses.
    • DZPN exhibited moderate cardiac depression at high concentrations and lacked intrinsic sympathomimetic activity (ISA).
    • Binding affinity studies revealed DZPN as a potent beta-adrenoceptor antagonist, comparable to atenolol and less potent than propranolol.

    Conclusions:

    • Dehydrozingeronolol (DZPN) functions as a beta-adrenoceptor antagonist with significant cardiovascular effects.
    • DZPN demonstrates selective antagonism of beta-adrenergic pathways, impacting heart rate and atrial function.
    • The findings support DZPN's potential as a therapeutic agent targeting beta-adrenergic receptors.